Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations (Q49112239)
Jump to navigation
Jump to search
scientific article published on 28 June 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations |
scientific article published on 28 June 2011 |
Statements
1 reference
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations (English)
1 reference
Shun Matsuura
1 reference
Naoki Inui
1 reference
Yuichi Ozawa
1 reference
Yutaro Nakamura
1 reference
Mikio Toyoshima
1 reference
Kazumasa Yasuda
1 reference
Takashi Yamada
1 reference
Toshihiro Shirai
1 reference
Hideki Suganuma
1 reference
Koji Yokomura
1 reference
Takafumi Suda
1 reference
Kingo Chida
1 reference
28 June 2011
1 reference
41
1 reference
8
1 reference
959-963
1 reference
Identifiers
1 reference
1 reference